TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Depreciation and Amortization

Last Annual Value

27.18M

3-Year CAGR

98%

5-Year CAGR

77%

10-Year CAGR

52%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of Depreciation and Amortization

TMDX · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
27.18M
49.2%71.8%51.5% 
18.00K
-14.7%-15.2%N/A
38.09M
0.1%2.0%23.2%
220.30M
24.2%19.8%15.0%
5.49M
-0.8%N/AN/A
8.31M
32.6%28.2%N/A
20.00M
10.1%-1.9%4.5%
220.00K
65.0%113.2%N/A
28.89M
-2.0%14.6%N/A
70.69M
4.4%0.5%12.6%
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
409.00K
28.4%-16.3%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69